Galapagos NV
NASDAQ:GLPG
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
24.2
42.44
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GLPG stock under the Base Case scenario is 34.96 USD. Compared to the current market price of 30.13 USD, Galapagos NV is Undervalued by 14%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Galapagos NV
Run backtest to discover the historical profit from buying and selling GLPG based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Galapagos NV
Balance Sheet Decomposition
Galapagos NV
Current Assets | 3.7B |
Cash & Short-Term Investments | 3.4B |
Receivables | 101.5m |
Other Current Assets | 133.2m |
Non-Current Assets | 625.2m |
Long-Term Investments | 51.4m |
PP&E | 128.5m |
Intangibles | 252.3m |
Other Non-Current Assets | 193m |
Current Liabilities | 364.8m |
Accounts Payable | 128.3m |
Other Current Liabilities | 236.5m |
Non-Current Liabilities | 1B |
Long-Term Debt | 6.7m |
Other Non-Current Liabilities | 1B |
Earnings Waterfall
Galapagos NV
Revenue
|
580.3m
EUR
|
Cost of Revenue
|
-311.8m
EUR
|
Gross Profit
|
268.5m
EUR
|
Operating Expenses
|
-458.3m
EUR
|
Operating Income
|
-189.8m
EUR
|
Other Expenses
|
526.5m
EUR
|
Net Income
|
336.7m
EUR
|
Free Cash Flow Analysis
Galapagos NV
EUR | |
Free Cash Flow | EUR |
GLPG Profitability Score
Profitability Due Diligence
Galapagos NV's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Galapagos NV's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
GLPG Solvency Score
Solvency Due Diligence
Galapagos NV's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Galapagos NV's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GLPG Price Targets Summary
Galapagos NV
According to Wall Street analysts, the average 1-year price target for GLPG is 43.64 USD with a low forecast of 33.61 USD and a high forecast of 64.06 USD.
Shareholder Yield
Current shareholder yield for GLPG is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
GLPG Price
Galapagos NV
Average Annual Return | -20.91% |
Standard Deviation of Annual Returns | 39.02% |
Max Drawdown | -91% |
Market Capitalization | 2B USD |
Shares Outstanding | 66 000 000 |
Percentage of Shares Shorted | 3.17% |
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 1,309 full-time employees. The company went IPO on 2005-05-06. The firm is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.
Contact
IPO
Employees
Officers
The intrinsic value of one GLPG stock under the Base Case scenario is 34.96 USD.
Compared to the current market price of 30.13 USD, Galapagos NV is Undervalued by 14%.